Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir

Bone Marrow Transplantation

Volumn 20, Issue 6, 1997, Pages 491-495

  Ippoliti, C ^a   Morgan, A ^a   Warkentin, D ^a   Van Besien, K ^a   Mehra, R ^a   Khouri, I ^a   Giralt, S ^a   Gajewski, J ^a   Champlin, R ^a   Andersson, B ^a   Przepiorka, D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Allogeneic; BMT; Cytomegalovirus; Foscarnet; Ganciclovir

Indexed keywords

FOSCARNET SODIUM; GANCICLOVIR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; FEMALE; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LIVER FAILURE; MALE; MORTALITY; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; PROPHYLAXIS; SEIZURE; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE; TREMOR; VIRUS REACTIVATION; VOMITING;

EID: 0030805973     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700910     Document Type: Article

References (16)

1. Goodrich JM, Bowden RA, Risher L et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118: 173-178.
2. Bowden RA, Meyers JD. Prophylaxis of cytomegalovirus. Semin Hematol 1990; 27 (Suppl. 1): 17-21.
3. Zaia JA. Epidemiology and pathogenesis of cytomegalovirus disease. Semin Hematol 1990; 27 (Suppl. 1): 5-10.
4. Meyers JD, Flournoy N, Thomas ED. Nonbacterial pneumonia after allogeneic marrow transplantation: a review of ten years experience. Rev Infect Dis 1982; 4: 119-132.
5. Winston DJ, Ho WG, Bartoni K et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann Intern Med 1993; 118: 179-184.
6. Minor JR, Baltz JK. Foscarnet sodium. DICP Ann Pharmacother 1991; 25: 41-47.
7. Crisp P, Clissold SP. Foscarnet. Drugs 1991; 41: 104-129.
8. Aschan J, Ringden O, Ljungman P et al. Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipients. Scand J Infect Dis 1992; 24: 143-150.
9. Ringden O, Lonnqvist B, Paulin T et al. Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. J Antimicrob Chemother 1986; 17: 373-387.
10. Reusser P, Gambertoglio JG, Lilleby K. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic transplant recipients. J Infect Dis 1992; 166: 473-479.
11. Bacigalupo A, Tedone E, Van Lint MT et al. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infection. Bone Marrow Transplant 1994; 13: 783-788.
12. Ringden O. Foscarnet as inpatient prophylaxis only is insufficient to prevent cytomegalo-virus infection after marrow transplantation. J Infect Dis 1993; 168: 1073.
13. Champlin R, Giralt S, Przepiorka D et al. Selective depletion of CD8-positive T-lymphocytes for allogeneic bone marrow transplantation: engraftment, graft-versus-host disease and graft-versus-leukemia. Prog Clin Biol Res 1992; 377: 385-393.
14. Przepiorka D, Ippoliti C, Panina A et al. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T-cell depleted marrow transplantation. Bone Marrow Transplant 1994; 13: 461-464.
15. Jacobson MA, Wulfsohn M, Feinberg JE et al. Phase II doseranging trial of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir (ACTG Protocol 093). AIDS 1994; 8: 451-459.
16. Jacobson MA, Kramer F, Bassiakos Y et al. Randomized phase I trial of two different combination foscarnet and ganciclovir chronic maintenance therapy regimens for AIDS patients cytomegalovirus retinitis: AIDS clinical trials group protocol 151. J Infect Dis 1994; 170: 189-193.